Hints and tips:
Related Special Reports
...Contributions from the company’s acquisitions — notably the $43bn purchase of cancer biotechnology company Seagen — have yet to move the needle....
...But Amyris had also branched out into being an incubator for beauty start-ups including Rose Inc, Costa Brazil and JVN hair care, and it proved too huge a leap from developing molecules to developing brands...
...A version of this article was first published by Nikkei Asia on January 26. ©2024 Nikkei Inc. All rights reserved....
...Nasdaq’s lower listing fees and costs mean many smaller companies choose to float there, including capital-hungry biotechnology groups which frequently tap the market for funds — generating fees for their...
...The Federal Trade Commission sued to block the biotechnology company Amgen’s $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said...
...Daina Graybosch, analyst at SVB Leerink, citing Paxlovid, Gilead Sciences’ remdesivir — an antiviral administered via injection — and monoclonal antibody therapy sotrovimab from GlaxoSmithKline and Vir Biotechnology...
...Pfizer is putting its Covid-19 windfall to work by splashing out $43bn to buy cancer biotechnology company Seagen....
...A cancer-focused biotechnology company has sued eight of the US’s largest market-making traders including Citadel Securities, Susquehanna and Virtu, alleging that they deliberately drove down its share price...
...On paper, Merck’s interest in buying the cancer biotechnology company SeaGen for about $40bn makes plenty of sense. The US drugmaker is flush with cash — to the tune of $8.6bn at the end of March....
...Merck & Co is in talks to buy the cancer biotechnology company SeaGen for about $40bn, according to two people familiar with the matter....
...The Nasdaq biotechnology index has shed nearly 27 per cent of its value this year. Prior to Tuesday’s deal announcement, Biohaven’s shares had fallen 40 per cent since January....
...Motif was launched by Boston-based biotechnology group Ginkgo Bioworks in 2019, and uses synthetic biology to create products for the plant-based food sector....
...The US Securities and Exchange Commission said that fast-food giant Yum China, biotechnology groups BeiGene, Zai Lab and HutchMed, and technology company ACM Research faced delisting....
...experts said the declining effectiveness of the two most commonly used antibody treatments has led to shortages of a third monoclonal antibody treatment sotrovimab, which is made by GlaxoSmithKline and Vir Biotechnology...
...Merck’s news hit shares in vaccine makers such as Moderna and BioNTech, as well as Vir Biotechnology, developer of a monoclonal antibody therapy in partnership with GlaxoSmithKline....
...The UK biotechnology group, which claims to have rights to “one of the most revolutionary treatments since the discovery of penicillin”, is hoping to float on the London Stock Exchange’s main market at a...
...Last week the German biotechnology group CureVac became the latest company to abandon a vaccine while the Maryland-based biotech Novavax has still not had its jab authorised in the US or Europe....
...“One of their struggles is going to be that investors are going to look for the next big thing,” said Hartaj Singh, senior biotechnology analyst at Oppenheimer....
...In August, she launched a skincare and make-up brand under the same name, developed with Caroline Hadfield of biotechnology company Amyris....
...Novavax has further delayed the submission of data for its Covid-19 vaccine to the US regulator as the biotechnology company continues to struggle with collating consistent manufacturing information....
...A version of this article was first published by Nikkei Asia on July 23. ©2022 Nikkei Inc. All rights reserved....
...infrastructure planThe huge government spending on US infrastructure announced by the president on Wednesday will include $180bn for research and development in areas such as artificial intelligence and biotechnology...
...AstraZeneca has named Alexion’s Aradhana Sarin as its new chief financial officer in a management reshuffle to plan around its $39bn acquisition of the US biotechnology company....
...The German biotechnology group said in its annual earnings report on Tuesday that increased output was possible thanks to optimised production processes and an expansion of its manufacturing and supply network...
...Instead, some say Michelle McMurry-Heath, the chief executive of the smaller Biotechnology Innovation Organization, might have more success....
International Edition